(function(){ var content_array=[" \n
GARFIELD-AF <\/b>簡介<\/b><\/p> \n
GARFIELD-AF 登記研究是一項獨立的學術性研究計劃。該登記研究是對最近確診房顛的病人開展的一項觀察性、多中心、全球性的前瞻性研究。它將對美洲、東歐與西歐、亞洲、非洲和澳洲35個國家至少1000個中心的50000名病人進行前瞻性跟蹤。<\/p> \n
當今對房顛的了解以臨床對照試驗中所收集的數據為基礎。在作為評估新療法有效性和安全性的基礎的同時,這些試驗無法代表日常臨床實踐。因此,有關該疾病的實際負擔和控制仍存在不確定性。GARFIELD-AF 尋求提供有關抗凝劑療法對這些病人群中發生血栓和流血併發症的影響的深刻見解。它將在具有代表性的多元化病人群和不同人群中提高護理與臨床效果的潛在機會方面提供深入瞭解。這將有助於醫師和醫療體系適當採用創新,從而為病人及人群確保最佳效果。<\/p> \n
這項登記研究於2009年12月開始。GARFIELD-AF 協議確保能夠對房顫進行全面典型描述的四大關鍵設計特點為:<\/p> \n
過去六週內,該計劃中的病人已被診斷出患有非瓣膜性房顫且至少伴有一項其它中風風險因素,並且他們還是預防中風誘因血栓形成的抗凝治療的潛在候選病人。研究人員的臨床判斷將確定病人的中風風險因素,但這些因素不限於既定風險評分中所包含的因素。無論是否接受抗凝治療,病人都將被納入計劃,以便正確掌握與病人風險情況相關的當前及未來的治療方案和失敗情況。<\/p> \n
拜耳醫藥保健集團 (Bayer Pharma AG) 為 GAGARFIELD-AF 登記計劃提供無限制研究經費。<\/p> \n
房顫負擔<\/b><\/p> \n
全球有多達2%的人口患有房顫。[1]<\/sup>歐洲約600萬人患有房顛[8]<\/sup>,美國300至500萬人患有房顫[9]<\/sup>,[10]<\/sup>中國多達800萬人患有房顛。[11],[12]<\/sup>到2050年,該患病規模預計隨著人口老化將至少翻番。房顫會使中風風險增加5倍,所有中風病例中有五分之一是由這種心律失常疾病引起的。房顫引起的缺血性中風常常是致命的,存活的病人中風頻率更高且傷害更大,而復發機率也比其它病因的中風病人要高。因此,房顫引起的中風的致命風險加倍,治療費用也增長了50%。[13]<\/sup> <\/p> \n 房顫表現為部分心房放射出不規則電信號,使心室過快且不規律地跳動,從而不讓血液完全流出心房。[14]<\/sup>結果,血液可能彙聚、凝結並引起血栓,這在發達國家和發展中國家都堪稱頭號殺手。如果血塊離開左心房,那麼它可能滯留在身體其它部位(特別是大腦)的動脈中。大腦動脈中的血塊會引起中風。92%的致命中風都由血栓引起。[15]<\/sup>房顫病人還是心臟衰竭、慢性疲勞以及其它心律疾病的高危人群。[16]<\/sup>在全球範圍內,中風是導致死亡和長期失能的主要病因,每年有670萬病人死亡[17]<\/sup>,500萬病人永遠喪失生活能力。[18]<\/sup><\/p> \n TRI <\/b>簡介<\/b><\/p> \n TRI 是一家慈善基金會和多學科研究所,致力於血栓和相關疾病的研究。TRI 的使命是提供卓越的血栓研究和教育;制定預防和治療血栓的新方案;從而提高治療質量,改善臨床療效和降低醫療費用。TRI 是 University College London Partners Academic Health Science System(倫敦大學學院合作夥伴學術醫療科學系統)的成員。<\/p> \n 更多信息請瀏覽:http:\/\/www.tri-london.ac.uk\/garfield<\/a> 。<\/p> \n 傳媒聯繫人<\/b><\/p> \n Emily Chu<\/span> 1. Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 2012; 14(11):1553-9. 8\/22\/14. Available at: http:\/\/europace.oxfordjournals.org\/content\/14\/11\/1553.long<\/a><\/p> \n 2. Kakkar AJ (2014, August). Introduction and status update of GARFIELD-AF. In AJ Kakkar and J-P Bassand (Co-chairs), Anticoagulation and AF: emerging insights. Symposium conducted at the ESC Congress 2014, Barcelona, Spain<\/span>.<\/p> \n 3. Haas S, Goto S, Fitzmaurice D, et al. International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD-AF Registry. Poster session presented at the ESC Congress 2014, Barcelona, Spain<\/span>.<\/p> \n 4. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21):2719-47. 8\/22\/14. Available at: http:\/\/eurheartj.oxfordjournals.org\/content\/33\/21\/2719.full<\/a><\/p> \n 5. Bassand JP, Goldhaber SZ, Camm J, et al. 'Truly low-risk' patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD-AF Registry. Poster session presented at the ESC Congress 2014, Barcelona, Spain<\/span>.<\/p> \n 6. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137:263-72. 8\/22\/14. Available at: http:\/\/journal.publications.chestnet.org\/article.aspx?articleid=1086288<\/a><\/p> \n 7. Bassand JP, Fitzmaurice D, Camm J, et al. Is cardiovascular death a primary driver of mortality in higher age groups of patients with non-valvular atrial fibrillation? Results from the GARFIELD-AF Registry. Poster session presented at the ESC Congress 2014, Barcelona, Spain<\/span>.<\/p> \n 8. The Lancet Neurology. Stroke prevention: getting to the heart of the matter. Lancet Neurol 2010; 9(2):129. 8\/22\/14. Available at: http:\/\/www.atrialfibrillation.org.uk\/files\/file\/Articles_Medical\/Lancet%20Neurology-%20getting%20to%20the%20heart%20of%20the%20matter.pdf<\/a><\/p> \n 9. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States<\/span>. Am J Cardiol 2009; 104(11):1534-9.<\/p> \n 10. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112(8):1142-7. 8\/22\/14. Available at: http:\/\/www.ajconline.org\/article\/S0002-9149(13)01288-5\/fulltext<\/a><\/p> \n 11. Zhou Z, Hu D. An<\/span> epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China<\/span>. J Epidermiol 2008; 18(5):209-16. 8\/22\/14. Available at: https:\/\/www.jstage.jst.go.jp\/article\/jea\/18\/5\/18_JE2008021\/_pdf<\/a><\/p> \n 12. Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China<\/span>. JACC 2008; 52(10):865-8. 8\/22\/14. Available at: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109708021141<\/a><\/p> \n 13. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 8\/22\/14. Eur Heart J 2010; 31(19):2369-429. 8\/22\/14. Available at: http:\/\/eurheartj.oxfordjournals.org\/content\/early\/2010\/09\/25\/eurheartj.ehq278.full<\/a><\/p> \n 14. National Heart, Lung, and Blood Institute. What is Atrial Fibrillation? 8\/22\/14. Available at: http:\/\/www.nhlbi.nih.gov\/health\/dci\/Diseases\/af\/af_what.html<\/a><\/p> \n 15. Thrombosis Research Institute. About Thrombosis. 8\/22\/14. Available at: http:\/\/www.tri-london.ac.uk\/about-us<\/a><\/p> \n 16. American Heart Association. Why Atrial Fibrillation (AF or AFib) Matters. 8\/22\/14. Available at: http:\/\/www.heart.org\/HEARTORG\/Conditions\/Arrhythmia\/AboutArrhythmia\/Why-Atrial-Fibrillation-AF-or-AFib-Matters_UCM_423776_Article.jsp<\/a><\/p> \n 17. World Health Organization. The top 10 causes of death. Fact sheet N°310. Updated May 2014<\/span>. 8\/22\/14. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/<\/a><\/p> \n 18. World Heart Federation. The global burden of stroke. 8\/22\/14. Available at: http:\/\/www.world-heart-federation.org\/cardiovascular-health\/stroke\/<\/a><\/p>"];
$("#dvExtra").html(content_array[0]);})();
電郵:echu@tri-london.ac.uk<\/a>
電話:+44(0)207-351-8300 轉 3383<\/p> \n